(ELN) Community Analysis from
Bulls REASONS TO BUY
|
62%
agree
8 votes
|
Is it time to buy Elan again ? |
Bears REASONS TO SELL
June 19, 2013
(Stock Blog Hub,
4/27/13)
Elan Corporation’s (ELN) Board of Directors recently responded to Echo Pharma Acquisition Limited’s (“Royalty Pharma”) offer to acquire Elan's shares under Rule 2.5 of the...(read more)
(Wealth Daily,
5/14/13)
Elan Corporation's (NYSE: ELN) has worked to soothe investor concern, and it's also added drug royalties to the company's assets...
(Stock Blog Hub,
2/11/13)
Elan Corporation plc (ELN) recently decided to sell its remaining 7.8 million ordinary shares in Alkermes plc (ALKS) pursuant to Rule 144 under the US Securities Act of...(read more)
Elan Corporation (ELN) Company Overview
Elan Corporation (NYSE:ELN) is a biotechnology company that makes drugs to treat Alzheimer’s disease, multiple sclerosis, Crohn’s disease and severe bacterial infections.[1]
(Read more at Wikinvest
) What's in this ELN analysis on Wikinvest...
